Holen Sie sich die Stockscreener-App
532.53
1.67%
-9.07
Handel nachbörslich:
532.53
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$541.60
Offen:
$534.65
24-Stunden-Volumen:
427.90K
Relative Volume:
0.97
Marktkapitalisierung:
$23.34B
Einnahmen:
$3.18B
Nettoeinkommen (Verlust:
$1.33B
KGV:
19.09
EPS:
27.9001
Netto-Cashflow:
$1.04B
1W Leistung:
+1.05%
1M Leistung:
+5.74%
6M Leistung:
+23.08%
1J Leistung:
+71.33%
1-Tages-Spanne:
$530.82
$541.16
1-Wochen-Bereich:
$517.59
$549.50
52-Wochen-Spanne:
$266.98
$549.50
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
532.53 | 23.74B | 3.18B | 1.33B | 1.04B | 27.90 |
TAK
Takeda Pharmaceutical Co Adr
|
18.06 | 57.78B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.63 | 49.27B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.75 | 43.48B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.78 | 34.31B | 17.41B | 1.43B | 1.00B | 1.2182 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Underweight |
| 2025-09-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
Rothblatt, United Therapeutics CEO, sells $5m in stock By Investing.com - Investing.com Australia
Rothblatt, United Therapeutics CEO, sells $5m in stock - Investing.com
United Therapeutics stock hits all-time high at 548.43 USD - Investing.com
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock - MarketBeat
United Therapeutics stock surges 32% in 6 months: Here's why - MSN
Insider Sell: Judy Olian Sells Shares of United Therapeutics Cor - GuruFocus
Rothblatt of United Therapeutics sells $5m in UTHR stock - Investing.com
United Therapeutics CFO Edgemond sells $5.27 million in UTHR stock - Investing.com
Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs Peers - TradingView
Rothblatt, United Therapeutics CEO, sells $4.9m in UTHR stock By Investing.com - Investing.com India
Rothblatt, United Therapeutics CEO, sells $4.9m in UTHR stock - Investing.com
[144] UNITED THERAPEUTICS Corp SE... | UTHR SEC FilingForm 144 - Stock Titan
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares under 10b5-1 plan - Stock Titan
UTHR (UTHR): Judy Olian to sell 200 shares under Form 144 notice - Stock Titan
Pulmonary Arterial Hypertension Market: Expanding Revenue Landscape to 2034 – DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therapeutics - Barchart
UTHR: Wells Fargo Raises Price Target for United Therapeutics | UTHR Stock News - GuruFocus
Dip Buying: Can United Therapeutics Corporation grow without dilution2026 Intraday Action & Verified Stock Trade Ideas - baoquankhu1.vn
If You Invested $1,000 in United Therapeutics Corp. (UTHR) - Stock Titan
Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Expands as 80+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart
United Therapeutics CEO Rothblatt sells $5m in UTHR stock - Investing.com UK
United Therapeutics CEO Rothblatt sells $5m in UTHR stock By Investing.com - Investing.com South Africa
Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics (UTHR) CEO exercises options and sells 9,500 shares under plan - Stock Titan
United Therapeutics (UTHR) EVP sells 8,300 shares after option exercise - Stock Titan
UTHR affiliate to sell 8,300 shares via option exercise (NASDAQ: UTHR) - Stock Titan
United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
Biotech Stocks Worth WatchingMarch 18th - MarketBeat
MannKind: Strategic Uncertainty Follows United Therapeutics' Pivot (Rating Downgrade) - Seeking Alpha
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells 9,500 Shares - TradingView
United Therapeutics (UTHR) COO exercises RSUs; 14,706 shares withheld for taxes - Stock Titan
United Therapeutics (UTHR) CFO exercises RSUs, shares withheld for taxes - Stock Titan
United Therapeutics (UTHR) legal chief vests 16,691 RSUs, nets 45,172 shares - Stock Titan
United Therapeutics (UTHR) CEO settles 69,579 RSUs with tax withholding - Stock Titan
United Therapeutics (UTHR) director sells 45 shares under 10b5-1 plan - Stock Titan
United Therapeutics Corporation $UTHR Holdings Lifted by L2 Asset Management LLC - MarketBeat
Assessing United Therapeutics (UTHR) Valuation After TETON-2 Tyvaso Data And New US$2b Buyback Program - simplywall.st
Rothblatt of United Therapeutics sells $5.1 million in UTHR stock - Investing.com
Judy Olian sells 400 UTHR shares across March transactions (UTHR) - Stock Titan
United Therapeutics CEO Martine A. Rothblatt Executes Stock Sales - TradingView
United Therapeutics (UTHR) director sells 200 shares under 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) CEO pre-planned option exercise and 9,500-share sale - Stock Titan
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 8,984 Shares - MarketBeat
United Therapeutics (NASDAQ:UTHR) CEO Sells $276,054.84 in Stock - MarketBeat
Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It - MSN
Rothblatt, United Therapeutics CEO, sells $5.1m in UTHR stock - Investing.com
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
Tyvaso IPF Data In NEJM Reframes United Therapeutics Growth Potential - Yahoo Finance
United Therapeutics Stock Surges 32% in 6 Months: Here's Why - TradingView
Van ECK Associates Corp Purchases 29,297 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Korea Investment CORP Has $5.90 Million Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
United Therapeutics Corp-Aktie (UTHR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 24 '26 |
Sale |
529.36 |
9,500 |
5,028,919 |
40,513 |
| EDGEMOND JAMES | CFO AND TREASURER |
Mar 23 '26 |
Option Exercise |
135.42 |
10,000 |
1,354,200 |
28,876 |
| EDGEMOND JAMES | CFO AND TREASURER |
Mar 23 '26 |
Sale |
527.48 |
10,000 |
5,274,802 |
18,876 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 23 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Mar 23 '26 |
Sale |
527.01 |
9,500 |
5,006,558 |
40,513 |
| Olian Judy D. | Director |
Mar 23 '26 |
Sale |
530.00 |
200 |
106,000 |
4,245 |
0.96%
0.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):